Endocarditis 200512-1233741644373579-2

56
Infective Endocarditis Matthew Leibowitz, MD David Geffen School of Medicine at UCLA Division of Infectious Diseases

Transcript of Endocarditis 200512-1233741644373579-2

Page 1: Endocarditis 200512-1233741644373579-2

Infective Endocarditis

Matthew Leibowitz, MDDavid Geffen School of Medicine at UCLA

Division of Infectious Diseases

Page 2: Endocarditis 200512-1233741644373579-2

Epidemiology• 10-20,000 cases per year in the US• Male:Female ratio 1.7:1• New trends

– Mean age was 30 in 1926, now > 50% of patients are over 60

– Decline in incidence of rheumatic fever– More prosthetic valves– More nosocomial cases, injected drug use– More staphylococcal infection

Page 3: Endocarditis 200512-1233741644373579-2

Epidemiology

• Mitral valve alone 28-45%• Aortic valve alone 5-36% (bicuspid

valve in 20% of all native valve IE)• Both mitral and aortic valves 0-36%• Tricuspid valve 0-6%• Pulmonic valve <1%• Right and left sided 0-4%

Page 4: Endocarditis 200512-1233741644373579-2

Classification

• OLD– Subacute Bacterial Endocarditis

• Death in 3-6 months– Acute Bacterial Endocarditis

• Death in < 6 weeks

• NEW– Native Valve Endocarditis– Prosthetic Valve Endocarditis

Page 5: Endocarditis 200512-1233741644373579-2

Pathogenesis• Alteration of the valvular endothelial

surface leading to deposition of platelets and fibrin

• Bacteremia with seeding of non-bacterial thrombotic vegetation (NBTE)

• Adherence and growth, further platelet and fibrin deposition

• Extension to adjacent structures– Papillary muscle, aortic valve ring abscess,

conduction system

Page 6: Endocarditis 200512-1233741644373579-2

Pathogenesis• Low pressure side of structural lesion

– Atrial side of mitral valve (MR)– Ventricular side of aortic valve (AR, AS with R)– Congenital abnormality (MV prolapse, bicuspid AV)– Scarring from rheumatic heart disease or sclerosis

as a consequence of aging– Prosthetic valves

• Other turbulence, high-velocity jets– Ventricular septal defect– Stenotic valve

• Direct mechanical damage from catheters, pacemaker leads

Page 7: Endocarditis 200512-1233741644373579-2

Pathogenesis• Transient bacteremia

– Traumatization of mucosal surface colonized with bacteria (oral, GI)

– Low grade, cleared in 15-30 minutes– Susceptibility to complement-mediated

bacterial killing• Leads to concept of prophylaxis

Page 8: Endocarditis 200512-1233741644373579-2
Page 9: Endocarditis 200512-1233741644373579-2

Microbiology• Staphylococcus aureus (30-40%)• Viridans group streptococci (18%)• Enterococci (11%)• Coagulase-negative staphylococci (11%)• Streptococcus bovis (7%)• Other streptococci (5%)• Non-HACEK Gram negatives (2%)• HACEK Organisms (2%)• Fungi (2%)• “Culture negative” (2-20%)

Page 10: Endocarditis 200512-1233741644373579-2

Characteristics of Causative Organisms

• Adherence factors critical for growth in the vegetation– Can adhere to damaged valves (Staph, Strep and

Enterococci have adhesins that mediate attachment)

– Staph adhesin binds fibrinogen and fibronectin– Bacteria trigger tissue-factor production from local

monocytes and induce platelet aggregation so the organisms become enveloped in the vegetation

– Protection from immune clearance leads to large numbers of bacteria (109-1010 per g of tissue)

Page 11: Endocarditis 200512-1233741644373579-2

Risk Factors

• Structural heart disease– Rheumatic, congenital, aging– Prosthetic heart valves

• Injected drug use• Invasive procedures (?)• Indwelling vascular devices• Other infection with bacteremia (e.g.

pneumonia, meningitis)• History of infective endocarditis

Page 12: Endocarditis 200512-1233741644373579-2

Clinical Manifestations• Symptoms

– Fever, sweats, chills– Anorexia, malaise, weight loss

• Signs– Anemia (normochromic, normocytic)– Splenomegaly– Microscopic hematuria, proteinuria– New or changing heart murmur, CHF– Embolic or immunologic dermatologic signs– Hypergammaglobulinemia, elevated ESR, CRP,

RF

Page 13: Endocarditis 200512-1233741644373579-2
Page 14: Endocarditis 200512-1233741644373579-2

Cardiac Pathologic Changes

• Vegetations on valve closure lines• Destruction and perforation of valve leaflet• Rupture of chordae tendinae,

intraventricular septum, papillary muscles• Valve ring abscess• Myocardial abscess• Conduction abnormalities

Page 15: Endocarditis 200512-1233741644373579-2

S. Aureus mitral valve vegetation, anterior leaflet

Page 16: Endocarditis 200512-1233741644373579-2
Page 17: Endocarditis 200512-1233741644373579-2

Pathologic Changes

• Kidney– Immune complex glomerulonephritis– Emboli with infarction, abscess

• Aortic mycotic aneurysms• Cerebral embolism

– Infarction, abscess, mycotic aneurysms– Purulent meningitis is rare

Page 18: Endocarditis 200512-1233741644373579-2
Page 19: Endocarditis 200512-1233741644373579-2

Pathologic Changes• Splenic enlargement, infarction• Septic or bland pulmonary embolism• Skin

– Petechiae– Osler nodes: diffuse infiltrate of neutrophils, and

monocytes in the dermal vessels with immune complex deposition. Tender and erythematous

– Janeway lesions: septic emboli with bacteria, neutrophils and SQ hemorrhage and necrosis. Blanching and non-tender. Palms and soles

Page 20: Endocarditis 200512-1233741644373579-2
Page 21: Endocarditis 200512-1233741644373579-2
Page 22: Endocarditis 200512-1233741644373579-2
Page 23: Endocarditis 200512-1233741644373579-2
Page 24: Endocarditis 200512-1233741644373579-2

Case Definition

• 1977 Pelletier and Petersdorf criteria • 1981 von Reyn criteria• 1994 Duke criteria• 2000 Modified Duke criteria

Page 25: Endocarditis 200512-1233741644373579-2

Modified Duke Criteria• Major Criteria

– Positive blood cultures with typical organisms

– Persistently positive blood cultures– Evidence of Endocardial involvement

• Positive Echocardiogram– Oscillating intracardiac mass– Abscess– Dehiscence of prosthetic valve

• New Valvular regurgitation

Page 26: Endocarditis 200512-1233741644373579-2

Modified Duke Criteria

• Minor Criteria– Predisposition (valvular disease or IDU)– Fever– Vascular phenomena (Arterial emboli,

septic pulmonary infarcts, intracranial hemorrhage, Osler, Janeway)

– Immunologic phenomena (GN, Osler, Roth spots, Rheumatoid Factor)

Page 27: Endocarditis 200512-1233741644373579-2

Modified Duke Criteria• Definite IE

– Pathologic criteria– Clinical criteria

• 2 Major Criteria OR• 1 Major and 3 minor Criteria OR• 5 Minor Criteria

• Possible IE• 1 Major and 1 Minor OR• 3 Minor

• Rejected IE

Page 28: Endocarditis 200512-1233741644373579-2

Blood Cultures• MULTIPLE BLOOD CULTURES

BEFORE EMPIRIC THERAPY• If not critically ill

– 3 blood cultures over 12-24 hour period– ? Delay therapy until diagnosis confirmed

• If critically ill– 3 blood cultures over one hour

• No more than 2 from same venipuncture• Relatively constant bacteremia

Page 29: Endocarditis 200512-1233741644373579-2

“Culture Negative” IE• Less common with improved blood

culture methods• Special media required

– Brucella, Mycoplasma, Chlamydia, Histoplasma, Legionella, Bartonella

• Longer incubation may be required– HACEK

• Coxiella burnetii (Q Fever), Trophyrema whipplei will not grow in cell-free media

Page 30: Endocarditis 200512-1233741644373579-2

HACEK

• Haemophilus aphrophilus, H. paraphrophilus, parainfluenzae

• Actinobacillus actinomycetemcomitans• Cardiobacterium hominis• Eikenella corrodens• Kingella kingae

Page 31: Endocarditis 200512-1233741644373579-2

Other microbiologic methods

• PCR– Coxiella burnetii– Tropheryma whipplei– Bartonella henselae

• Serology– Coxiella burnetii– Bartonella– Brucella– Legionella– Chlamydophila psittaci

Page 32: Endocarditis 200512-1233741644373579-2

Echocardiography

• Transthoracic– Relatively low sensitivity– Good specificity

• Transesophageal– Detection of valve ring abscess (87% vs.

28% sensitivity for TTE)– Detection of prosthetic valve IE

Page 33: Endocarditis 200512-1233741644373579-2

When to go to TEE first?

• Limited thoracic windows = TTE low sensitivity

• Prosthetic valves• Prior valvular abnormality• S. aureus bacteremia and suspected IE• Bacteremia with organisms likely to

cause IE= high prior probability of IE

Page 34: Endocarditis 200512-1233741644373579-2

Other tests

• Electrocardiogram– Conduction delays– Ischemia or infarction

• Chest X-ray– Septic emboli in right-sided IE– Valve calcification– CHF

Page 35: Endocarditis 200512-1233741644373579-2

Treatment of IE

• Native vs. Prosthetic Valve• Bactericidal therapy is necessary• Eradication of bacteria in the vegetation

– May be metabolically inactive (stationary phase)

– May need higher concentrations of antimicrobial agents

Page 36: Endocarditis 200512-1233741644373579-2

Antimicrobial Therapy

• Most patients are afebrile in 3-5 days• Long duration of therapy (4-6 weeks or

more)• Combination therapy most important for

– Shorter course regimens– Enterococcal endocarditis– Prosthetic valve infections

Page 37: Endocarditis 200512-1233741644373579-2

Native Valve IE

• Viridans Streptococci and S. bovis– Aqueous Penicillin G 12-20 million

units/day continuously or divided q4 or q6 for 4 weeks

– If intermediate susceptibility to penicillin, aqueous penicillin G 24 million units or ceftriaxone 2 g q24 PLUS aminoglycoside for the first 2 weeks

Page 38: Endocarditis 200512-1233741644373579-2

Native Valve IE

• Aminoglycosides for synergy– Low concentrations are adequate (1-3

mcg/ml)– Gentamicin 3 mg/kg divided q12 or q8– Little data for q24 dosing

Page 39: Endocarditis 200512-1233741644373579-2

Native Valve IE• Enterococci, ampicillin sensitive

– High rates of failure– β-lactams are bacteriostatic, must combine with

aminoglycoside for optimal therapy– High-level gentamicin resistance occurs in 35%

• High-dose ampicillin for 8-12 weeks

• Enterococci, ampicillin resistant– Vancomycin plus gentamicin

• Enterococci, vancomycin resistant– Linezolid or daptomycin– Penicillin + vancomycin + gentamicin ?

Page 40: Endocarditis 200512-1233741644373579-2

Native Valve IE

• S. aureus– Penicillinase-resistant semi-synthetic

penicillin (oxacillin or nafcillin) 1.5-2 g IV q4 or cephalosporin (cefazolin 1-2 g IV q8) for 4-6 weeks

– Aminoglycoside synergistic but does not affect survival, not recommended

– Short course in right-sided IE• 2 weeks of semi-synthetic penicillin and

aminoglycoside

Page 41: Endocarditis 200512-1233741644373579-2

Native Valve IE

• Methicillin-resistant S. aureus– Vancomycin is bacteriostatic– Vancomycin plus aminoglycoside or

rifampin– Daptomycin– Linezolid

Page 42: Endocarditis 200512-1233741644373579-2

Native Valve IE

• HACEK– Ceftriaxone 2 g IV q 24 x 4-6 weeks

• Fungal– Amphotericin– Fluconazole– Caspofungin, little data– Surgery usually necessary 1-2 weeks into

treatment

Page 43: Endocarditis 200512-1233741644373579-2

Native Valve IE• Indications for surgery

– Refractory CHF– More than one systemic embolic event– Uncontrolled infection– Physiologically significant valvular

dysfunction– Ineffective antimicrobial therapy (e.g.

fungal)– Local suppurative complications– Mycotic aneurysm

Page 44: Endocarditis 200512-1233741644373579-2

Prosthetic Valve IE

• Staphylococci most common– Coagulase negative staphylococci

• Enterococcus• Nutritonally variant streptococci• Fungi

Page 45: Endocarditis 200512-1233741644373579-2

Prosthetic Valve IE

• Risk is greatest in the first 3 months and first year (early PV IE)– Coagulase-negative staphylococci in early

endocarditis, S. aureus– Late-onset more similar to native valve

disease in microbiology but more coagulase-negative staphylococci. Valve is endothelialized

Page 46: Endocarditis 200512-1233741644373579-2

Prosthetic Valve IE

• TEE should be used first• Staphylococci

– Vancomycin or oxacillin plus rifampin for at least six weeks, gentamicin for the first two weeks (3 mg/kg q24)

– Rifampin started at least 2 days after 2 other agents to avoid resistance

Page 47: Endocarditis 200512-1233741644373579-2
Page 48: Endocarditis 200512-1233741644373579-2
Page 49: Endocarditis 200512-1233741644373579-2

Prophylaxis of IE

• Uncertainty and controversy• No randomized trials• Indirect evidence (uncontrolled clinical

series, case-control studies)• Decision analysis

Page 50: Endocarditis 200512-1233741644373579-2
Page 51: Endocarditis 200512-1233741644373579-2
Page 52: Endocarditis 200512-1233741644373579-2
Page 53: Endocarditis 200512-1233741644373579-2
Page 54: Endocarditis 200512-1233741644373579-2

Clinical Case

• 43 yo man ESRD, Cadaveric Renal Transplant 2004

• Recurrent UTIs, placement of nephrostomy tube

• Fevers, chills, altered mental status, sepsis syndrome

• Bradycardia to 35 and increased PR

Page 55: Endocarditis 200512-1233741644373579-2

Clinical Case• Urine with MRSA, 4/4 blood cultures with MRSA• Initial TTE: EF 35-45%, thickened AV with moderate

AS, thickened or calcified MV mild MR– “Compared with last previous echo, 3/3/00, there is no

significant change. In the presence of valvular thickening, cannot rule out endocarditis.

• Next day TEE– thickened AV, mild to moderate AS, no AR. 2 vegetations

~1 cm on ventricular side– Markedly thickened MV, large mobile vegetation >4cm on

atrial side anterior leaflet, possible second vegetation on posterior leaflet, mild MR

Page 56: Endocarditis 200512-1233741644373579-2

Clinical case

• Renal allograft removed the following day with abscess

• Replacement of AV and MV and resection of left ventricular abscess cavity two days later